Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Authors:
- Loren LaineLLLoren Laine
- Sean P CurtisSCSean P Curtis
- Byron CryerBCByron Cryer
- Amarjot KaurAKAmarjot Kaur
- Christopher P CannonCCChristopher P Cannon
- MEDAL Steering CommitteeMCMEDAL Steering Committee
- 1 February 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 369 (9560) , 465-473
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 34 references indexed in Scilit:
- Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisAmerican Heart Journal, 2006
- The impact of low‐dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non‐selective non‐steroidal anti‐inflammatory drug or a cyclo‐oxygenase‐2‐selective inhibitorAlimentary Pharmacology & Therapeutics, 2006
- Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I StudyThe American Journal of Medicine, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Meta‐analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase‐2‐specific inhibitor, compared with nonspecific nonsteroidal anti‐inflammatory drugs among patients with osteoarthritis and rheumatoid arthritisAlimentary Pharmacology & Therapeutics, 2005
- Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trialRheumatology, 2003
- Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.Gastroenterology, 2003
- Preventing Recurrent Upper Gastrointestinal Bleeding in Patients withHelicobacter pyloriInfection Who Are Taking Low-Dose Aspirin or NaproxenNew England Journal of Medicine, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988